$ELAN

Elanco Animal Health (ELAN) fell 3.36% after Jefferies downgraded it to hold and cut its price target. Patterson-UTI (PTEN) dropped 3.49% due to lower oil prices. GE Aerospace (GE) declined 3.67% following strong Q3 earnings, while Howmet Aerospace (HWM) fell 3.82% on lack of new catalysts.

Wall Street analysts released research calls on various companies. Upgrades include Akamai (AKAM) to Strong Buy, BlackRock (BLK) to Buy, and Venture Global (VG) to Overweight. Downgrades include Apple (AAPL) to Hold, Elanco (ELAN) to Hold, and Zoetis (ZTS) to Hold. Initiations include Ford (F) with Overweight and Sunoco (SUN) with Overweight. Markets were mixed, with Nasdaq futures lower and Treasury yields higher.

Jefferies downgraded Elanco Animal Health (ELAN) to Hold, cutting its price target to $24 from $31. The stock trades at $23.49, with InvestingPro suggesting overvaluation. Analysts cite growth driven by volume, not pricing, and note risks from Zoetis' concessions. Elanco reported Q2 2026 earnings of $0.34 per share on $1.37B revenue, beating estimates. Fitch upgraded Elanco's rating to 'BB+' from 'BB', while Stifel maintained a Buy rating with a $33 target.

Jefferies downgraded Zoetis (ZTS) to Hold from Buy, lowering its price target to $83 from $103. The firm cited concerns about pricing headwinds and lower volume growth, projecting a 2% decline in 2027 EPS. Jefferies also downgraded Elanco to Hold, citing pricing risks, while Fitch upgraded Elanco's ratings and Stifel reiterated a Buy rating.

Purdue University and Elanco Animal Health (ELAN) launched the One Health Research Institute, a 150,000 sq ft facility for One Health innovation in Indianapolis. The institute will focus on research, collaboration, and commercialization in interconnected health areas. Purdue will provide academic support, while Elanco will offer industry expertise. The project aims to establish Indianapolis as a global hub for One Health research and innovation.

Elanco Animal Health completed a $120 million expansion of its biologics plant in Kansas, increasing capacity fourfold. The company plans to invest an additional $30 million by 2028, aiming for unconstrained supply of its dermatology product Befrena by early 2027, as demand is twice expectations.

Elanco Animal Health (NYSE: ELAN) will release its Q3 2026 financial results on November 6, 2026, followed by a conference call at 8:00 a.m. ET. The call will be webcast live and a replay will be available later. Elanco is a global animal health company focused on products for farm animals and pets.

Elanco Animal Health completed a $120M expansion of its Kansas biologics plant, increasing production capacity 4x. The site now serves as the company's center for monoclonal antibody (mAb) manufacturing, with plans for an additional $30M investment by 2028. Elanco acquired the site in 2021 and has since grown its workforce from 30 to over 200 employees. The expansion supports products like Trutect and Befrena, with demand for the latter exceeding expectations.

Elanco Animal Health completed a $150M expansion in Kansas, boosting monoclonal antibody production for products like Befrena and Trutect. The expansion supports revenue growth and future therapy development but also introduces risks related to higher operating costs. Elanco projects $5.8B revenue and $297.2M earnings by 2029, with analysts offering varied outlooks on its future performance.

The FDA approved Capstar (Elanco) and nitenpyram (Felix) for preventing and treating New World screwworm in pets. The drugs are for dogs, cats, and kittens over 4 weeks old. 48 cases confirmed in the U.S. according to the USDA. Elanco and Felix are the manufacturers.